|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||95.33 - 97.17|
|52 Week Range||69.38 - 125.86|
|PE Ratio (TTM)||23.99|
|Earnings Date||Jul 27, 2018|
|Forward Dividend & Yield||3.84 (3.96%)|
|1y Target Est||113.05|
AbbVie Inc said on Tuesday it signed a U.S. licensing deal with Mylan NV for its proposed biosimilar to AbbVie's blockbuster drug Humira, in a move that will give it more near-term control over the competition. The deal is in line with AbbVie's strategy to fend off rivals of the world's best-selling prescription drug until 2023, giving the company more time to bolster its pipeline with new cash cows to offset the expected sales decline. Humira, which treats rheumatoid arthritis, raked in $18.43 billion in sales last year and accounted for nearly two-thirds of AbbVie's net revenue.
NORTH CHICAGO, Ill., July 17, 2018 /PRNewswire/ -- AbbVie (ABBV) announced today patent license agreements with Mylan over its proposed biosimilar adalimumab product. Under the terms of the agreements, AbbVie will grant Mylan a non-exclusive license on specified dates to AbbVie's intellectual property relating to HUMIRA in the United States and in various other countries around the world in which AbbVie has intellectual property, excluding Europe.
Calico is a life sciences company focused on aging research and therapeutics. Together, AbbVie and Calico have produced more than two dozen early-stage programs for disease states across oncology and neuroscience since 2014. The agreement has extended the AbbVie-Calico collaboration for three years.
On July 12, AbbVie (ABBV) announced that it had submitted an sNDA (supplemental new drug application) to the FDA for venetoclax for treating newly diagnosed AML (acute myeloid leukemia) patients not eligible for intensive chemotherapy. AML is an aggressive form of cancer with very low rates of survival and few available options for patients who are ineligible for intensive chemotherapy. The FDA has granted the drug two breakthrough therapy designations for AML.
News of positive clinical data for its Alzheimer’s study lifted the entire biotechnology sector. Oddly enough, markets largely ignored pharmaceutical stocks, choosing instead to invest in the riskier biotech sector. The following are Big Pharma stocks that should be on the radar of most investors.
Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.
Stagnant deal activity has investors "losing patience with the large cap pharma sector," according to a note from Goldman Sachs analyst Jami Rubin. Small- and mid-cap biotech companies are being valued at all time highs, and companies are staying away from new acquisitions for fear of paying high premiums for them, Rubin wrote. "Pharma management teams are facing investor pressure to put their capital to work, but balancing the risk of overpaying with the risk of doing nothing has led to low levels of deal activity thus far this year in our view," Rubin said.
AbbVie's (ABBV) Imbruvica fails to meet the primary endpoint in a phase III study evaluating the drug in patients with DLBCL, a rare blood cancer, who have received no prior treatment.
It's still really early for research from the collaboration between AbbVie and Alphabet's Calico, but the payoff could be huge.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 11) AC Immune SA (NASDAQ: ACIU ) Arbutus Biopharma Corp (NASDAQ: ...
On July 11, AbbVie (ABBV) announced an update from its phase three study of Ibrutinib for blood cancer diffuse large B-cell lymphoma (or DLBCL) and the ibrutinib clinical program, which is exploring the potential of the molecule as a single or combination therapy for multiple cancers as well as other diseases. This study is focusing on a subtype of DLBCL that has poorer treatment outcomes.
Less than 48 hours after Donald Trump took to Twitter to say the company “should be ashamed” of raising prices on 100 products, the drugmaker demurred and said it would defer the increases. also followed a series of thinly veiled warnings from Alex Azar, the health secretary, who said its decision to raise prices this month would “be remembered for creating a tipping point in US drug pricing policy”. The company said it would defer the increases until the end of the year or until Mr Trump implements his “blueprint to strengthen the healthcare system” — a complex string of measures announced in May, aimed at lowering drug prices.
– Acute myeloid leukemia (AML) is one of the most aggressive cancers, with a very low survival rate and few options available for patients who are ineligible for intensive chemotherapy – Median survival ...
Biotech is a notoriously risky business. Many biotechnology products do not produce the desired results consistently, while others fail to gain acceptance in the marketplace. Of course, when a biotech product succeeds, investors can make a lot of money.
Among the companies with shares expected to trade actively in Wednesday's session are Boeing, Ford, American Airlines, Pfizer and Comcast.
MARKET PULSE Shares of AbbVie Inc. (abbv) fell 2.2% in premarket trade Wednesday, after the biopharmaceutical company said an update on a phase 3 study evaluating the addition of ibrutinib to a chemotherapy regimen failed to meet its primary endpoint of improving event-free survival.
- The ibrutinib clinical program is designed to fully explore the potential of this first-in-class molecule as a single or combination therapy for multiple cancers and other diseases. Fourteen Phase 3 ...
LONDON, UK / ACCESSWIRE / July 11, 2018 / Active-Investors has a free review on AbbVie Inc. (NYSE: ABBV) following the Company's announcement that it will begin trading ex-dividend on July 12, 2018. To capture the dividend payout, investors must purchase the stock a day prior to the ex-dividend date that is by latest at the end of the trading session on July 11, 2018. Active-Investors has initiated due-diligence on this dividend stock.
The Zacks Analyst Blog Highlights: Apache, Continental Resources, KMG Chemicals, ZAGG and AbbVie
NORTH CHICAGO, Ill. , July 10, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its second-quarter 2018 financial results on Friday, July 27, 2018 ...
It’s time to celebrate President Trump’s second year in office. Given the bullishness, investing in stocks with solid growth potential doesn’t seem to be a bad proposition. There is always a 67% chance that the U.S. stock market will scale north during the second years of presidential terms.